Suppr超能文献

自闭症谱系障碍中注意力不集中、多动及冲动行为的治疗。

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

作者信息

Aman Michael G, Farmer Cristan A, Hollway Jill, Arnold L Eugene

机构信息

Department of Psychology, Ohio State University, 225 Psychology Building, 1835 Neil Avenue, Columbus, OH 43210, USA.

出版信息

Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):713-38, vii. doi: 10.1016/j.chc.2008.06.009.

Abstract

We reviewed the recent literature on medicines used to manage inattention, impulsiveness, and overactivity in children with pervasive developmental disorders (autistic disorder, pervasive developmental disorder not otherwise specified, Asperger's disorder) using computer searches of pharmacologic studies. A substantial number of reports were identified and summarized. The literature tends to be dominated by uncontrolled studies, although the number of controlled trials is growing. Findings are described for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, alpha adrenergic agonists, antidepressants, anxiolytics, cholinesterase inhibitors, N-methyl-D-aspartate receptor blockers, and antiepileptic mood stabilizers. Evidence for a positive effect is strongest for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, and alpha adrenergic agonists. Evidence for efficacy seems weakest for newer antidepressants, anxiolytics, and mood stabilizers.

摘要

我们通过对药理学研究进行计算机检索,回顾了近期有关用于治疗广泛性发育障碍(自闭症谱系障碍、未特定的广泛性发育障碍、阿斯伯格综合征)儿童注意力不集中、冲动和多动的药物的文献。我们识别并总结了大量报告。尽管对照试验的数量在增加,但文献仍以非对照研究为主。文中描述了精神兴奋剂、去甲肾上腺素能再摄取抑制剂、抗精神病药物、α肾上腺素能激动剂、抗抑郁药、抗焦虑药、胆碱酯酶抑制剂、N-甲基-D-天冬氨酸受体阻滞剂及抗癫痫心境稳定剂的研究结果。精神兴奋剂、去甲肾上腺素能再摄取抑制剂、抗精神病药物及α肾上腺素能激动剂产生积极效果的证据最为充分。新型抗抑郁药、抗焦虑药及心境稳定剂的疗效证据似乎最为薄弱。

相似文献

1
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.
Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):713-38, vii. doi: 10.1016/j.chc.2008.06.009.
2
Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.
J Autism Dev Disord. 2000 Oct;30(5):451-9. doi: 10.1023/a:1005559725475.
3
[Psychopharmacology of autistic disorders].
Z Kinder Jugendpsychiatr Psychother. 2007 Mar;35(2):87-94. doi: 10.1024/1422-4917.35.2.87.
4
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
J Child Adolesc Psychopharmacol. 2004 Summer;14(2):233-41. doi: 10.1089/1044546041649084.
5
Pharmacotherapy to control behavioral symptoms in children with autism.
Expert Opin Pharmacother. 2012 Aug;13(11):1615-29. doi: 10.1517/14656566.2012.674110. Epub 2012 May 3.
6
Use of clonidine in children with autism spectrum disorders.
Brain Dev. 2008 Aug;30(7):454-60. doi: 10.1016/j.braindev.2007.12.007. Epub 2008 Feb 15.
7
Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
CNS Drugs. 2009;23 Suppl 1:43-9. doi: 10.2165/00023210-200923000-00006.
8
[Algorithms for the medical treatment of Attention-Deficit/Hyperactivity Disorder with specific co-morbidities].
Z Kinder Jugendpsychiatr Psychother. 2010 Jan;38(1):7-20. doi: 10.1024/1422-4917.a000002.

引用本文的文献

1
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options.
Pharmaceuticals (Basel). 2025 Feb 25;18(3):324. doi: 10.3390/ph18030324.
4
Targeting Shank3 deficiency and paresthesia in autism spectrum disorder: A brief review.
Front Mol Neurosci. 2023 Feb 9;16:1128974. doi: 10.3389/fnmol.2023.1128974. eCollection 2023.
5
Anti-inflammatory properties of commonly used psychiatric drugs.
Front Neurosci. 2023 Jan 10;16:1039379. doi: 10.3389/fnins.2022.1039379. eCollection 2022.
6
Children with autism spectrum disorder show increased sensitivity to time-based predictability.
Int J Dev Disabil. 2019 Feb 7;66(3):214-221. doi: 10.1080/20473869.2018.1564447.
9
Prevalence and Risk-Markers of Self-Harm in Autistic Children and Adults.
J Autism Dev Disord. 2020 Oct;50(10):3561-3574. doi: 10.1007/s10803-019-04260-1.
10
The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review.
Neuropsychiatr Dis Treat. 2019 Jun 6;15:1547-1555. doi: 10.2147/NDT.S194022. eCollection 2019.

本文引用的文献

1
Ziprasidone in adolescents with autism: an open-label pilot study.
J Child Adolesc Psychopharmacol. 2007 Dec;17(6):779-90. doi: 10.1089/cap.2006.0126.
3
A prospective, open-label trial of galantamine in autistic disorder.
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):621-9. doi: 10.1089/cap.2006.16.621.
6
A prospective open trial of guanfacine in children with pervasive developmental disorders.
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):589-98. doi: 10.1089/cap.2006.16.589.
7
Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):561-73. doi: 10.1089/cap.2006.16.561.
10
A retrospective study of memantine in children and adolescents with pervasive developmental disorders.
Psychopharmacology (Berl). 2007 Mar;191(1):141-7. doi: 10.1007/s00213-006-0518-9. Epub 2006 Oct 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验